Search

Displaying results 3161 - 3170 of 5506 in total
  1. Drug

    Rabies virus inactivated antigen, A

    go.drugbank.com/drugs/DB10283
    ApprovedInvestigational

    It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.

  2. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

  3. Drug

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14196
    Approved

    It is also a dermatological sensitizer and allergen. Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.

  4. Drug

    Famciclovir

    go.drugbank.com/drugs/DB00426
    ApprovedInvestigational

    It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.

  5. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

  6. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    Across two 52-week placebo-controlled trials, enlicitide 20 mg once daily reduced LDL-C at Week 24 by 56% relative to placebo in patients with hypercholesterolemia at established or increased ASCVD risk … It is formulated as enlicitide decanoate alongside the permeation enhancer sodium caprate, which facilitates absorption of the peptide across the gastrointestinal tract, though oral bioavailability remains

  7. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name

  8. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    [L53798] Later the same year, it was approved in the US for the same indication. [L54216] … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.

  9. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    It is found within many commercially available cosmetics, lotions, and makeup removers. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.

  10. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.